Breaking Finance News

Ionis Pharmaceuticals Inc (NASDAQ:IONS) has been upgraded to C- in a statement by TheStreet today.

TheStreet has upgraded Ionis Pharmaceuticals Inc (NASDAQ:IONS) to C- in a report released on 07/05/2017.

Previously on Monday April 03, 2017, Vetr Inc. reported on Ionis Pharmaceuticals Inc (NASDAQ:IONS) increased the target price from $0.00 to $37.67. At the time, this indicated a possible downside of -0.06%.

Yesterday Ionis Pharmaceuticals Inc (NASDAQ:IONS) traded 2.63% higher at $53.23. The company’s 50-day moving average is $52.52 and its 200-day moving average is $46.92. The last closing price is up -0.34% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time period. 2,627,979 shares of the stock traded hands, up from an average trading volume of 1,406,890

Performance Chart

Ionis Pharmaceuticals Inc (NASDAQ:IONS)

With a total market value of $0, Ionis Pharmaceuticals Inc has price-earnings ratio of 224.81 with a one year low of $24.58 and a one year high of $60.01 .

A total of 9 equity analysts have released a ratings update on IONS. One equity analyst rating the company a strong buy, five equity analysts rating the company a buy, five equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally 1 firm rating the stock a sell with a consensus target price of $52.56.

About Ionis Pharmaceuticals Inc (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.